Arctic Bioscience AS Company Profile

Background

Overview

Arctic Bioscience AS is a Norwegian biotechnology company specializing in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products derived from bioactive marine compounds, particularly those found in herring roe. Established in 2011, the company is headquartered in Ørsta, Norway, strategically located on the west coast to access sustainable fisheries and clean sea water. Arctic Bioscience is publicly listed on Euronext Growth Oslo under the ticker symbol ABS.

Mission and Vision

The company's mission is to provide effective and healthy therapies for individuals with autoimmune disorders, utilizing novel marine membrane lipids. Arctic Bioscience envisions becoming a leading provider of innovative marine-based treatments and supplements, contributing to global health and well-being.

Primary Area of Focus

Arctic Bioscience focuses on two main areas:

1. Pharmaceuticals: Developing novel oral treatments for autoimmune conditions, with a primary emphasis on mild-to-moderate psoriasis.

2. Nutraceuticals: Producing high-quality marine Omega-3 phospholipid extracts and proteins from herring roe, marketed under the ROMEGA® brand.

Industry Significance

The company plays a pivotal role in the biotechnology sector by harnessing marine resources to create unique bioactive compounds. Its innovative approach addresses significant unmet medical needs, particularly in the treatment of autoimmune disorders, and contributes to the growing demand for sustainable and natural nutraceutical products.

Key Strategic Focus

Core Objectives

• Pharmaceutical Development: Advance the clinical development of HRO350, a novel oral drug candidate for treating mild-to-moderate psoriasis.

• Nutraceutical Expansion: Enhance the global presence of ROMEGA® products through both business-to-consumer (B2C) and business-to-business (B2B) channels.

Specific Areas of Specialization

• Marine Membrane Lipids: Expertise in extracting and utilizing bioactive compounds from herring roe to develop therapeutic and nutritional products.

• Clinical Research: Conducting rigorous clinical trials to substantiate the efficacy and safety of pharmaceutical candidates.

Key Technologies Utilized

• Bioreactor Technology: Following the acquisition of Arctic Algae AS in 2023, Arctic Bioscience has integrated innovative bioreactor technologies for scalable microalgae production, enhancing the extraction of marine membrane lipids.

• Proprietary Extraction Methods: Developing unique processes to extract high-quality marine oils and proteins from herring roe.

Primary Markets Targeted

• Pharmaceuticals: Patients with mild-to-moderate psoriasis, primarily in the European and North American markets.

• Nutraceuticals: Global consumers seeking premium Omega-3 supplements, with a focus on markets in Europe, the United States, and Asia.

Financials and Funding

Funding History

• Initial Public Offering (IPO): Arctic Bioscience went public on Euronext Growth Oslo in February 2021, raising gross proceeds of NOK 250 million.

• Private Placement: In February 2021, the company conducted a private placement, securing NOK 250 million in gross proceeds to support its strategic initiatives.

Recent Funding Rounds

• Post-IPO Debt: The company has engaged in multiple post-IPO debt rounds to bolster its financial position and fund ongoing projects. Specific details regarding these rounds are not publicly disclosed.

Notable Investors

• Ronja Capital II AS: A significant shareholder and investor in Arctic Bioscience, contributing to the company's growth and strategic direction.

Utilization of Capital

• Pharmaceutical Development: Funding the clinical development of HRO350, including Phase IIb trials for psoriasis treatment.

• Manufacturing Expansion: Investing in state-of-the-art production facilities to enhance manufacturing capabilities and product quality.

• Research and Development: Supporting ongoing R&D efforts to innovate and expand the product portfolio.

Pipeline Development

Key Pipeline Candidates

• HRO350: A novel oral drug candidate derived from herring roe, currently in Phase IIb clinical trials for the treatment of mild-to-moderate psoriasis.

Stages of Clinical Trials

• Phase IIb Trials: Designed in line with recommendations from the European Medicines Agency, these trials aim to evaluate the efficacy and safety of HRO350 in patients with mild-to-moderate psoriasis.

Target Conditions

• Mild-to-Moderate Psoriasis: A chronic autoimmune condition characterized by the rapid growth of skin cells, leading to scaling and inflammation.

Anticipated Milestones

• Clinical Trial Initiation: Scheduled for the first quarter of 2022, with results expected in subsequent quarters.

Technological Platform and Innovation

Proprietary Technologies

• Marine Membrane Lipid Extraction: Utilizing unique methods to extract bioactive compounds from herring roe, ensuring high purity and efficacy.

• Bioreactor Technology: Incorporating advanced bioreactor systems for scalable microalgae production, enhancing the sustainability and efficiency of raw material sourcing.

Significant Scientific Methods

• Clinical Trials: Conducting rigorous clinical studies to validate the therapeutic potential of marine-derived compounds.

• Bioprocess Optimization: Employing advanced bioprocessing techniques to maximize yield and quality of marine extracts.

Leadership Team

Key Executives

• Christer L. Valderhaug: Chief Executive Officer (CEO). With extensive experience in marine oils and global pharmaceutical companies, he leads Arctic Bioscience's strategic direction.

• Tore Tønseth: Board Member. Serving as the Investment Director of Ronja Capital II AS, he brings valuable insights into investment strategies and corporate governance.

• Danielle Glenn: Chief Financial Officer (CFO). Responsible for overseeing the company's financial operations and strategic financial planning.

Competitor Profile

Market Insights and Dynamics

The biotechnology sector, particularly in the realm of marine-derived pharmaceuticals and nutraceuticals, is experiencing significant growth. There is an increasing demand for natural and sustainable products, positioning companies like Arctic Bioscience favorably in the market.

Competitor Analysis

• Eurofins Scientific: A global group offering laboratory services, including bioanalytical testing.

• Incyte Corporation: A biopharmaceutical company focusing on the discovery and development of novel therapeutics.

• Apnimed: Specializes in the development of therapies for sleep apnea and other sleep disorders.

Strategic Collaborations and Partnerships

• Kotler Marketing Group: A strategic partner for sales and marketing in the Greater China region, enhancing Arctic Bioscience's market reach.

Operational Insights

Arctic Bioscience's focus on sustainable sourcing and innovative extraction methods provides a competitive edge in producing high-quality marine-derived products. The integration of bioreactor technology for microalgae production further strengthens its position in the market.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Product Development: Advance the clinical development of HRO350 and expand the nutraceutical product line.

• Market Expansion: Increase global presence through strategic partnerships and enhanced distribution channels.

• Manufacturing Excellence: Invest in state-of-the-art facilities to support large-scale production and maintain product quality.

Future Business Directions

Arctic Bioscience aims to solidify its position as a leader in marine-derived therapeutics and supplements, addressing global health challenges with innovative solutions.